Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
2,570 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06732336 | HER2-PET Imaging in HER2-low Breast Cancers | recruiting | Phase 1 / Phase 2 | 40 | Centre de recherche du Centre hospitalier universitaire de SherbrookeOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07420517 | Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer(DutaBCa-1) | recruiting | Phase 2 | 95 | Paul TorenOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT00066443 | Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer | completed | Phase 1 / Phase 2 | 93 | NCIC Clinical Trials GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT00428142 | Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma | completed | Phase 2 | 95 | NCIC Clinical Trials GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03297606 | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)(CAPTUR) | recruiting | Phase 2 | 720 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03568422 | CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 37 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04663997 | 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer | active not recruiting | Phase 2 | 200 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03288545 | A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer(EV-103) | terminated | Phase 1 / Phase 2 | 348 | Astellas Pharma Global Development, Inc.INDUSTRY | 6 | Mar 24, 2026 | clinicaltrials |
| NCT03410615 | Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC | active not recruiting | Phase 2 | 129 | Canadian Cancer Trials GroupNETWORK | 4 | Mar 24, 2026 | clinicaltrials |
| NCT04008797 | A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 301 | Eisai Inc.INDUSTRY | 10 | Mar 24, 2026 | clinicaltrials |
| NCT04988555 | A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | recruiting | Phase 1 / Phase 2 | 606 | Sumitomo Pharma America, Inc.INDUSTRY | 12 | Mar 24, 2026 | clinicaltrials |
| NCT04639219 | A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations(DPT01) | active not recruiting | Phase 2 | 102 | AstraZenecaINDUSTRY | 9 | Mar 23, 2026 | clinicaltrials |
| NCT05656794 | Consolidative Prostate Radiotherapy in Metastatic Prostate Cancer(CONSORT-PC) | recruiting | Phase 2 | 40 | University Health Network, TorontoOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT06409910 | Comparing Moderately Ultra Hypofractionated Radiation Treatments for Prostate Cancer(AMPORA) | recruiting | Phase 2 | 204 | University Health Network, TorontoOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT02503423 | Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | active not recruiting | Phase 1 / Phase 2 | 253 | Taiho Oncology, Inc.INDUSTRY | 8 | Mar 20, 2026 | clinicaltrials |
| NCT02773030 | A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 466 | CelgeneINDUSTRY | 11 | Mar 20, 2026 | clinicaltrials |
| NCT05361668 | Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome | completed | Phase 2 | 36 | Crinetics Pharmaceuticals Inc.INDUSTRY | 7 | Mar 19, 2026 | clinicaltrials |
| NCT06036836 | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | completed | Phase 2 | 163 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Mar 19, 2026 | clinicaltrials |
| NCT03441958 | ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma | completed | Phase 1 / Phase 2 | 19 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04699188 | Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation(KontRASt-01) | active not recruiting | Phase 1 / Phase 2 | 344 | Novartis PharmaceuticalsINDUSTRY | 16 | Mar 18, 2026 | clinicaltrials |
| NCT04814108 | A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma | completed | Phase 2 | 92 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT02467270 | Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses(OPTIC) | completed | Phase 2 | 283 | TakedaINDUSTRY | 21 | Mar 17, 2026 | clinicaltrials |
| NCT03070392 | Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | completed | Phase 2 | 378 | Immunocore LtdINDUSTRY | 14 | Mar 17, 2026 | clinicaltrials |
| NCT07476794 | Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma(TEMPO) | recruiting | Phase 2 | 118 | Sunnybrook Health Sciences CentreOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05907954 | (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | active not recruiting | Phase 2 | 160 | IDEAYA BiosciencesINDUSTRY | 7 | Mar 16, 2026 | clinicaltrials |
| NCT05950594 | IVIM & OLINK in Sarcoma | recruiting | Phase 2 | 145 | University Health Network, TorontoOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06736704 | SNV4818 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 320 | Pikavation Therapeutics, Inc.INDUSTRY | 3 | Mar 13, 2026 | clinicaltrials |
| NCT04300647 | A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer(SKYSCRAPER-04) | completed | Phase 2 | 172 | Hoffmann-La RocheINDUSTRY | 17 | Mar 12, 2026 | clinicaltrials |
| NCT02723994 | A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia | completed | Phase 2 | 171 | Incyte CorporationINDUSTRY | 3 | Mar 11, 2026 | clinicaltrials |
| NCT02285816 | MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 56 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 9, 2026 | clinicaltrials |
| NCT02905318 | Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 2 | 19 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05573555 | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) | active not recruiting | Phase 1 / Phase 2 | 20 | PfizerINDUSTRY | 4 | Mar 9, 2026 | clinicaltrials |
| NCT00160979 | Transrectal Tumour Oxygen - US Army | completed | Phase 2 | 186 | University Health Network, TorontoOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT00188539 | Cervix: Hypoxia, Interstitial Fluid Pressure and GSH Levels | active not recruiting | Phase 2 | 346 | University Health Network, TorontoOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT01761929 | 5 Fraction Stereotactic Body Radiation Therapy for Oligometastases Regimen, for Extra-Cranial Oligometastases(5fr SBRT) | completed | Phase 2 | 138 | University Health Network, TorontoOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT01803542 | Stereotactic Radiotherapy (SBRT) of Lung Metastasis(SBRT Lung) | recruiting | Phase 2 | 200 | University Health Network, TorontoOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04262466 | Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | active not recruiting | Phase 1 / Phase 2 | 410 | Immunocore LtdINDUSTRY | 17 | Mar 6, 2026 | clinicaltrials |
| NCT00797719 | Short Neoadjuvant Hemithoracic IMRT for MPM | completed | Phase 1 / Phase 2 | 104 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04197297 | Brain Imaging Biomarkers in Patients With Brain Metastasis | recruiting | Phase 2 | 90 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04563338 | An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) | active not recruiting | Phase 2 | 36 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05008900 | Timing of Post-prostatectomy PSMA Imaging(TOPP) | completed | Phase 2 | 4 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06710197 | IL-1 Inhibition in Early TNBC(OZM-034) | withdrawn | Phase 2 | 0 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04416984 | Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)(ALPHA2) | active not recruiting | Phase 1 / Phase 2 | 160 | Allogene TherapeuticsINDUSTRY | 3 | Mar 4, 2026 | clinicaltrials |
| NCT06815666 | BAL Fluid Biomarkers in Sarcoma | recruiting | Phase 2 | 70 | University Health Network, TorontoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05218499 | Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma | completed | Phase 2 / Phase 3 | 400 | Boehringer IngelheimINDUSTRY | 22 | Mar 2, 2026 | clinicaltrials |
| NCT01068782 | Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse | terminated | Phase 2 | 19 | ExelixisINDUSTRY | 2 | Feb 25, 2026 | clinicaltrials |
| NCT05414032 | Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC(MERIDIAN) | recruiting | Phase 2 | 102 | University Health Network, TorontoOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT03400332 | A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers | completed | Phase 1 / Phase 2 | 281 | Bristol-Myers SquibbINDUSTRY | 12 | Feb 24, 2026 | clinicaltrials |
| NCT04059484 | Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer(AMEERA-3) | terminated | Phase 2 | 367 | SanofiINDUSTRY | 23 | Feb 24, 2026 | clinicaltrials |
| NCT06016387 | Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study | recruiting | Phase 2 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Feb 23, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials